Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Accepted for publication February 9, 2022
- Published online June 1, 2022.
Article Versions
- Latest version (March 1, 2022 - 04:00).
- Latest version (May 2, 2022 - 10:00).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright © 2022 by the Journal of Rheumatology This is an Open Access article, which permits use, distribution, and reproduction, without modification, provided the original article is correctly cited and is not used for commercial purposes.
Author Information
- Philip G. Conaghan1,
- Robert H. Dworkin2,
- Thomas J. Schnitzer3,
- Francis Berenbaum4,
- Andrew G. Bushmakin5,
- Joseph C. Cappelleri5,
- Lars Viktrup6 and
- Lucy Abraham7⇑
- 1P.G. Conaghan, MB BS, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds, UK;
- 2R.H. Dworkin, PhD, University of Rochester, Rochester, New York, USA;
- 3T.J. Schnitzer, MD, PhD, Northwestern University, Evanston, Illinois, USA;
- 4F. Berenbaum, MD, PhD, Sorbonne Université, Paris, France;
- 5A.G. Bushmakin, MS, J.C. Cappelleri, PhD, Pfizer Inc, Groton, Connecticut, USA;
- 6L. Viktrup, MD, PhD, Eli Lilly and Co., Indianapolis, Indiana, USA;
- 7L. Abraham, MSc, CPsychol, Pfizer Ltd, Surrey, UK.
- Address correspondence to L. Abraham, Pfizer Ltd, 1-G Walton Oaks, Dorking Road, Walton on the Hill, Tadworth, Surrey KT20 7NS, UK. Email: Lucy.Abraham{at}pfizer.com.
